文献速递胸部肿瘤

恶性胸膜间皮瘤DNA损伤修复基因新发胚系突变

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
PubMed 文献 · J Thorac Oncol · 2019-12-28

该研究对84例恶性胸膜间皮瘤患者血液样本行MSK-IMPACT NGS检测,发现12%(10/84)携带致病性胚系变异,涉及DNA损伤修复基因如MSH3、BRCA1相关RING域1、RECQL4等,且携带者一级亲属癌症家族史更常见(40% vs 12%,p<0.05)。

要点

  • 12%的MPM患者携带致病性胚系变异,支持DNA损伤修复基因在MPM发病中的作用。
  • 新发现MSH3、BRCA1相关RING域1、RECQL4等致病性胚系变异。
  • 携带胚系致病性变异者一级亲属中超过两人患癌的比例更高(40% vs 12%)。

核心结论

  • DNA损伤修复基因胚系变异在恶性胸膜间皮瘤发病中起作用,针对这些通路成员的筛查和治疗值得进一步研究。

研究设计与样本

  • 对84例恶性胸膜间皮瘤患者的血液样本使用MSK-IMPACT NGS平台分析癌症易感基因,鉴定功能丧失变异或致病性条目并收集临床病理信息。

主要发现

  • 84例患者中12%(10/84)携带致病性变异,携带者与未携带者临床特征相似。
  • 携带胚系致病性变异者一级亲属中超过两人患癌的比例高于无胚系突变者(40% vs 12%;Fisher精确检验,p<0.05)。
  • 新发现的致病性变异包括MSH3(1%[1/84];95%CI:0%-7%)、BRCA1相关RING域1(1%[1/84];95%CI:0%-7%)和RECQL4(2%[2/84];95%CI:0%-9%)。
  • 既往报道的致病性变异包括BAP1(4%[3/84];95%CI:1%-10%)、BRCA2(1%[1/84];95%CI:0%-7%)和MRE11(1%[1/84];95%CI:0%-7%)。
  • 1例患者(1%[1/84];95%CI:0%-7%)携带SHQ1的可能致病性改变,该基因尚未与癌症遗传易感性关联。

临床怎么用

  • 对恶性胸膜间皮瘤患者可考虑胚系基因检测,尤其是有多名一级亲属患癌家族史者。
  • 检测到的DNA损伤修复基因变异可能为筛查和靶向治疗提供依据,但需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although next-generation sequencing (NGS) has brought insight into critical mutations or pathways (e.g., DNA damage sensing and repair) involved in the etiology of many cancers and has directed new screening, prevention, and therapeutic approaches for patients and families, it has only recently been used in malignant pleural mesotheliomas (MPMs). METHODS: We analyzed the blood samples from patients with MPM using the NGS platform MSK-IMPACT to explore cancer-predisposing genes. The loss-of-function variants or pathogenic entries were identified, and clinicopathologic information was collected. RESULTS: Of 84 patients with MPM, 12% (10 of 84) had pathogenic variants. Clinical characteristics were similar between cohorts, although patients with germline pathogenic variants were more likely to have more than two first-degree family members with cancer than those without germline mutations (40% versus 12%; Fisher's exact test, p < 0.05). Novel, deleterious variants in mesotheliomas included MutS homolog 3 (1% [one of 84]; 95% confidence interval [CI]: 0%-7%), breast cancer gene 1-associated ring domain 1 (1% [one of 84]; 95% CI: 0%-7%), and RecQ-like helicase 4 (2% [two of 84]; 95% CI: 0%-9%). Pathogenic variants previously reported on germline testing in patients with mesotheliomas were breast cancer gene 1-associated protein 1 (4% [three of 84]; 95% CI: 1%-10%), breast cancer gene 2 (1% [one of 84]; 95% CI: 0%-7%), and MRE11 homolog, double strand break repair nuclease (1% [one of 84]; 95% CI: 0%-7%). One patient (1% [one of 84]; 95% CI: 0%-7%) had a likely pathogenic alteration in SHQ1, H/ACA ribonucleoprotein assembly factor that has not been associated with a heritable susceptibility to cancer. CONCLUSIONS: Our study lends further support for the role of aberrations in DNA damage repair genes in the pathogenesis of MPMs and suggests that targeting the members of these pathways for screening and treatment warrants further study.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Guo R, DuBoff M, Jayakumaran G, et al. Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. J Thorac Oncol. 2019. PMID: 31887429. doi:10.1016/j.jtho.2019.12.111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。